|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Investment in hotel properties, net of accumulated depreciation and amortization of $30,989,984 and $33,318,590 | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Franchise fees, net | ||||||||||||||||||||
| Prepaid expenses and other assets | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Total Assets (variable interest entities - $21,140,527 and $22,117,277) | ||||||||||||||||||||
| Liabilities and Equity | ||||||||||||||||||||
| Debt, net | ||||||||||||||||||||
| Finance lease liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Distributions payable | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Mandatorily redeemable Series P preferred units, net | ||||||||||||||||||||
| Liabilities related to assets held for sale | ||||||||||||||||||||
| Total liabilities (variable interest entities - $17,465,166 and $17,011,733) | ||||||||||||||||||||
| Equity | ||||||||||||||||||||
| Common stock, $0.01 par value, 900,000,000 shares authorized; 10,016,043 and 10,011,475 shares issued and outstanding | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Non-controlling interest | ||||||||||||||||||||
| Series B LP Units | ||||||||||||||||||||
| Series GO LP Units | ||||||||||||||||||||
| Series GO 2LP Units | ||||||||||||||||||||
| Series Go 2LP Units | ||||||||||||||||||||
| Series T LP Units | ||||||||||||||||||||
| Series Pref A Units | ||||||||||||||||||||
| Common LP Units | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total Liabilities and Equity | ||||||||||||||||||||
Loading...
